Liraglutide injection is now approved for adult and pediatric patients ages 10 and up, proving another option amid the GLP-1 ...

In 2024, the most-read articles published in Population Health, Equity & Outcomes (PHEO) highlighted the promise of ...

One lawmaker said the CT Department of Social Services told him the agency wasn’t paying for FDA-approved drugs because of ...

Body mass index (BMI) and obesity prevalence declined in the United States in 2023, according to a research letter published ...

Today, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 ...

Takers of GLP-1 are reportedly going on a "holiday pause" to enjoy meal centric family celebrations. Here, an MD breaks down the risks of the trend.

The U.S. Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the ...

FDA has approved the first prescription drug, Zepbound, for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

The US Food and Drug Administration approved a generic once-daily injectable version of the glucagon-like peptide-1 receptor ...

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.

The approval marks the second for a generic in this class of medications indicated to improve glycemic control in patients ...

Today, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1) ...